Tuesday, May 12, 2026
dark cloud cover candlestick 如何使用
乌云盖顶（Dark Cloud Cover）是一种看跌的K线反转形态，通常出现在上升趋势的末端，预示着市场买盘力量减弱，空方开始反攻，股价可能从上涨转为下跌。
1. 形态特征
乌云盖顶由两根K线组成：
- 第一天（阳线）： 一根强劲的阳线（绿色或白色），通常带有较大的实体，延续之前的上升趋势。
- 第二天（阴线）： 价格高开，但随后下跌，最终阴线（红色或黑色）的收盘价低于第一天阳线实体的一半（50%）位置。
- 关键点： 第二天收盘跌入第一天实体的一半以下，显示出空方力量在反扑。
2. 使用方法与交易策略
3. 与类似形态的区别
此视频展示了如何将乌云盖顶与刺透形态结合使用：
Canada tax return marginal account loss can tax deduction or not
Yes, realized investment losses in a Canadian taxable margin account are generally tax-deductible. These capital losses can offset capital gains in the current year, be carried back three years to reduce previous taxes, or carried forward indefinitely to reduce future taxes. Note that losses cannot offset regular income, and you cannot claim losses if you repurchase the same security within 30 days (Superficial Loss Rule).
Key Details on Marginal Account Losses (2026):
- Capital Loss Mechanism: A capital loss happens when you sell an investment in a non-registered margin account for less than its adjusted cost base (ACB), which is the purchase price plus fees.
- Offsetting Gains: Capital losses must first be used to reduce capital gains in the current year.
- Net Capital Losses: If your losses exceed your gains, you have a net capital loss, which can be applied to capital gains in the three preceding years or any future year (using Form T1A).
- Superficial Loss Rule: If you sell a security for a loss and buy the same or identical security within 30 days (before or after), the loss is considered "superficial" and cannot be claimed, but it can be added to the ACB of the new investment.
- Interest Deductibility: Interest paid on money borrowed to invest in a margin account is generally tax-deductible, as it is used to earn income, as explained in CRA rules on interest deductions.
- What You Can't Do: You cannot use capital losses from a margin account to reduce regular income (like employment income).
3 Reasons to Buy AbbVie Stock (ABBV) Like There's No Tomorrow Motley Fool - Tue May 12, 9:50AM CDT
Key Points
AbbVie has a long history of paying and increasing its dividend, and it recently yielded 3.4%.
It has shown that its able to generate fresh revenue as new drugs come on line.
The biotech stock's valuation looks reasonable at recent levels, too.
If you're in the market for a healthcare stock for your long-term portfolio, give some consideration to AbbVie(NYSE: ABBV). It's a drug company that was spun off from Abbott Laboratories in 2013, and there are multiple reasons you might want to invest in it.
Here's a closer look at AbbVie, and at some of those reasons to consider it.
Meet AbbVie
Here are some things to know about AbbVie:
- It boasts 12 blockbuster products that generated more than $1 billion in revenue in 2025.
- It has invested more than $85 billion in research and development since 2013.
- It treats more than 75 health conditions.
- Its stock has averaged annual gains of about 15% over the past decade.
Here are some key reasons it's a promising investment.
1. It's a dividend payer
AbbVie is a dividend-paying stock, with a recent dividend yield of 3.4%. Better still, it has a solid track record of increasing its payouts -- by more than 330% since 2013. Consider that it's now paying a total annual dividend sum of $6.92 per share, up from $4.72 in 2020 and $2.28 in 2016.
2. It's got a rich pipeline
The future of any pharmaceutical company rests on its pipeline of treatments in development. AbbVie is impressive in this regard, with around 90 such treatments in development, in-house, in collaboration, or via license. The company notes that around 60 of those are in mid- or late-stage development, meaning that they're getting much closer to consideration for approval by the Food and Drug Administration (FDA). Better still, five have been fast-tracked in one way or another.
AbbVie has shown the power of an effective pipeline in its recent history. Many investors were worried about what would happen when its antirheumatic drug Humira lost its U.S. patent exclusivity in 2023, but the company is making up for that with Humira's fast-selling successors, Skyrizi and Rinvoq. The company is also showing strength in its neuroscience portfolio, led by Vraylar and Botox, and in cancer treatments, with its drugs Elahere and Epkinly.
3. Its valuation is reasonable
Finally, AbbVie's stock, while not bargain-priced at recent levels, also doesn't seem too pricey. Its recent forward-looking price-to-earnings (P/E) ratio of 14 is only a bit above its five-year average of 13. Those numbers don't seem high at all for a company that recently reported year-over-year first-quarter revenue growth of 12.4% (10.3% on an operational basis).
That revenue is likely to increase robustly, too. Revenue from Skyrizi jumped 30.9% year over year in the first quarter, while Rinvoq's revenue popped by 23.3%. Long-term investors, especially those seeking income, should give AbbVie a closer look.
Should you buy stock in AbbVie right now?
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $460,826!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,345,285!*
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
inverted hammer candlestick pattern 如何使用
倒锤子线（Inverted Hammer）是一种看涨的单根K线反转形态，通常出现在下跌趋势的底部，预示着卖方力量可能减弱，买方开始反攻，价格可能即将反转向上。
以下是如何使用倒锤子线进行交易的详细指南：
1. 识别倒锤子线形态
2. 确认信号（重要）
3. 具体交易步骤 (买入策略)
Subscribe to:
Posts (Atom)